Sanofi ends research in diabetes, narrows units to spur profit
By Matthias Blamont PARIS (Reuters) - Sanofi SA said on Monday it would end its research efforts in diabetes and cardiovascular diseases as part of a revamp that will narrow the number of its business units in the hope of bolstering growth and profit.
By Matthias Blamont
PARIS (Reuters) - Sanofi SA
The French drugmaker, whose pipeline has disappointed investors in recent years, poached new chief executive Paul Hudson from Swiss pharma group Novartis
Its move to ditch diabetes research - announced alongside cost savings targets - marks a major turning point for a firm whose products dominated the insulin market for nearly two decades, before it was hit by patent losses and a drop in sales.
"We recognise it is getting more difficult to get breakthrough innovation and that we have to be efficient and move our resources to areas of opportunity, as tough a choice as that is," Hudson told reporters.
The firm is bulking up elsewhere, as in the lucrative field of cancer drugs. It announced a deal to buy U.S. biotechnology firm Synthorx
Sanofi, which is due to further detail strategic plans to investors on Tuesday in Cambridge, Massachusetts, said it was targeting new cost savings of 2 billion euros (1.7 billion pounds) by 2022, by tightening spending and shaking up its supply chain.
It also aims for a core operating margin of 30% by then, up from 25.8% last year.
The group emphasized the potential for its eczema treatment Dupixent, recently approved in other therapeutic areas such as asthma, with an aim to expand sales to more than 10 billion euros.
Revenue for the drug, developed with U.S. partner Regeneron Pharmaceuticals Inc
Sanofi, currently organised around five global business units, said it would rejig these around three pillars: specialty care, which includes oncology and rare diseases, as well as vaccines and general medicines.
Its consumer healthcare unit - known for over-the-counter products such as paracetamol Doliprane, erectile dysfunction drug Cialis and influenza treatment Tamiflu - will be considered as a standalone business, Sanofi said.
It would have its own operational dynamic, the firm added, though it did not clarify what this meant in the longer term.
Sources told Reuters last month that Sanofi was considering a joint venture or an outright sale among options for the division.
"Our objective for the consumer healthcare business is to unlock value and entrepreneurial energy by growing faster than the market over mid-term," Hudson said.
(Reporting by Matthias Blamont in Paris; Editing by Sarah White and Matthew Lewis)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
DAKAR (Reuters) - More than 20 people, including children, were killed in an airstrike during a wedding ceremony in central Mali on Sunday, a health worker with knowledge of the attack told Reuters. (Reporting By Edward McAllister; Editing by Aaron Ross)
By Estelle Shirbon and Natalie Thomas LONDON (Reuters) - Britain began its third COVID-19 lockdown on Tuesday with the government calling for one last major national effort to defeat the spread of a virus that has infected an estimated one in 50 citizens before mass vaccinations turn the tide. Finance minister Rishi Sunak announced a new package of business grants worth 4.6 billion pounds ($6.2 billion) to help keep people in jobs and firms afloat until measures are relaxed gradually, at the earliest from mid-February but likely later
By Dominique Vidalon and Sudip Kar-Gupta PARIS (Reuters) - France is stepping up its COVID-19 vaccine rollout by widening the first target group to include more health workers and simplifying a cumbersome process to deliver shots more quickly, Health Minister Olivier Veran said on Tuesday. France's inoculation campaign got off to a slow start, hampered in part by red tape and President Emmanuel Macron's decision to tread warily in one of the world's most vaccine-sceptical countries. France has fallen behind neighbours such as Britain and Germany, and the president is now demanding the vaccination programme be expedited